META-ANALYSIS OF RISK OF STROKE AND THROMBO-EMBOLISM WITH RIVAROXABAN VERSUS VITAMIN K ANTAGONISTS IN ABLATION AND CARDIOVERSION OF ATRIAL FIBRILLATION

Few trials explore safety and efficacy of rivaroxaban in ablation and cardioversion (DCCV) procedures of atrial fibrillation (AFIB). We aim to explore the hypothesis that rivaroxaban results in equal outcomes compared to Vitamin K Antagonists (VKA) in these procedures. We searched the online